Profit before deduction of interest, taxes, depreciation and amortization: Phio Pharmaceuticals (PHIO)
The financial EBITDA metric demonstrates profit dynamics, where the value of 0.00 serves as the current indicator. The Phio Pharmaceuticals (PHIO) business is not subject to market cycles or seasonality, maintaining resilience against macro shocks. High barriers to entry are ensured by INTASYL patents and strict FDA control. The foundation for success is rooted in breakthrough RNA self-delivery technology, which enables the effective blocking of genes associated with dangerous diseases.
Summary analytical data breakdowns for Phio Pharmaceuticals Corp. (PHIO)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- book capitalization indicators:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Phio Pharmaceuticals|PHIO - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Phio Pharmaceuticals Corp|PHIO - Company Aggregate Debts|Debts to Book Capitalization Phio Pharmaceuticals|PHIO - Company Long-Term Debts|Company Current Liabilities Phio Pharmaceuticals|Immediate Liquidity phiopharma.com
- earnings and market ratios statistics:
PHIO - Net Income|Projected Future Earnings Phio Pharmaceuticals|PHIO - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Phio Pharmaceuticals Corp|PHIO - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Phio Pharmaceuticals|PHIO - Operating profit EBITDA|Net earnings per share for the last 12 months Phio Pharmaceuticals|PHIO - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth phiopharma.com|PHIO - Earnings per share growth in current year|Net earnings per share growth forecast for next year Phio Pharmaceuticals
Summary company analytics:PHIO (Phio Pharmaceuticals)
The development of the INTASYL oncology platform requires colossal expenditures for Phio Pharmaceuticals (PHIO), making the company's absolute operating profit in cash terms a critical marker of resource management efficiency. This indicator aggregates cash flow from core operations before interest and taxes, allowing investors to assess the business's real solvency and the pace of innovation scaling between quarterly reports.
Who Phio Pharmaceuticals competes with
Income before deduction of interest, taxes and amortization TEM|QGEN - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization IONS|RGEN: Operating profit EBITDA|Avidity Biosciences Inc - Income before deduction of interest, taxes and amortization|CRSP (CRISPR Therapeutics Corp) - Operating profit EBITDA|Operating profit EBITDA GeneDx Corp|Profit before payment of interest, taxes and amortization Ultragenyx Pharmaceutical (RARE)|BEAM (beamtx.com) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Sarepta SRPT|TWST - Operating profit before deduction of amortization|10x Genomics Corp - Operating profit EBITDA|NTLA - Operating profit EBITDA|STOK: Operating profit EBITDA|Operating profit before deduction of amortization biolifesolutions.com|WVE (Wave Life Sciences Ltd.) - Operating profit EBITDA|Profit before interest, taxes and amortization Maze Therapeutics, Inc. MAZE|Operating profit before deduction of amortization SION (Sionna Pharma)|Operating profit EBITDA Prime Medicine Bio (PRME)|Taysha Gene Therapies - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization QURE (uniqure.com)|MeiraGTx - Operating profit EBITDA|Operating income before deduction of amortization REGENXBIO Inc RGNX|SLDB: Operating profit EBITDA|Operating profit before deduction of amortization Ocugen Pharma|PACB (Pacific Biosciences) - Operating profit EBITDA|Operating profit EBITDA benitec.com|Profit before payment of interest, taxes and amortization Design Therapeutics, Inc. (DSGN)|Profit before payment of interest, taxes and amortization RCKT (Rocket Pharma)|Profit before payment of interest, taxes and amortization 4D Molecular Therapeutics Inc FDMT|Operating income before deduction of amortization Lexeo Therapeutics Inc. (LXEO)|KRRO - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization EDIT|SLN: Operating profit EBITDA|ProQR Therapeutics - Income before deduction of interest, taxes and amortization|CDXS (Codexis Inc) - Operating profit EBITDA|Sangamo BioSciences (SGMO) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Nautilus Biotechnology (NAUT)|MGX - Profit before interest, taxes and amortization|Operating profit EBITDA DTIL (Precision BioSciences, Inc.)|GBIO: Operating profit before amortization|BOLD - Profit before payment of interest, taxes and amortization|XCUR (Exicure, Inc.) - Operating profit before amortization|IMNN: Operating profit EBITDA|Mustang Bio (MBIO) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization TransCode Therapeutics Inc.|Bionano - Profit before deduction of interest, taxes, depreciation and amortization|Operating profit EBITDA APDN|BLUE (bluebird bio, Inc) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA IPA (ImmunoPrecise Antibodies Ltd.)|Operating income before deduction of amortization omegatherapeutics.com (OMGA)|OMIC - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Regulus Therapeutics, Inc.|SYRS (Syros) - Operating profit before deduction of amortization|Telesis Bio, Inc - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization TRACON Pharmaceuticals|unitybiotechnology.com - Profit before deduction of interest, taxes, depreciation and amortization
